Compare LOCL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | NEPH |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | LOCL | NEPH |
|---|---|---|
| Price | $2.53 | $4.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.7K | ★ 75.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $45,978,000.00 | $17,930,000.00 |
| Revenue This Year | $36.93 | $33.32 |
| Revenue Next Year | $82.62 | $12.27 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | 31.61 | ★ 32.36 |
| 52 Week Low | $1.18 | $1.39 |
| 52 Week High | $5.75 | $6.42 |
| Indicator | LOCL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 47.81 |
| Support Level | $2.48 | $4.83 |
| Resistance Level | $2.70 | $5.97 |
| Average True Range (ATR) | 0.21 | 0.62 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 63.64 | 26.90 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.